Superworth

Tenax Therapeutics price to book ratio TENX

Market value divided by the book value of the company's net assets, since 2013.

Today, Oct 23, 2026
0.6×
10-year median
1.0×
Against its 10-year history
25th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.1× to 30.8×
Peer median
1.5×

Tenax Therapeutics' price to book ratio is 0.6× as of Oct 23, 2026.

That is below its ten-year median of 1.0×, lower than on 75% of days in the last ten years.

Over that time it ranged from 0.1× in Mar 2024 to 30.8× in Oct 2021.

The median for 9 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.6×0.4×4.5×
20250.8×0.2×0.9×
20240.2×0.1×1.8×
20230.6×0.3×7.0×
20221.3×0.4×10.2×
20213.6×3.0×30.8×
20203.2×0.5×6.7×
20191.3×0.3×1.3×
20180.4×0.4×1.3×
20171.4×0.4×1.5×
20161.2×0.8×1.4×
20151.4×1.1×1.5×
20141.4×0.4×27.4×
201318.0×5.8×30.9×

Against its peers

Companies in Drug Manufacturers - General nearest Tenax Therapeutics' size, closest first, today.

CompanyPrice to book ratio
TENXTenax Therapeutics0.6×
SPROSpero Therapeutics1.5×
LFVNLifevantage2.2×
ATNMActinium Pharmaceuticals1.6×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Tenax Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.